Elicera Therapeutics AB

OSTO:ELIC (Sweden)   Ordinary Shares
kr 1.28 (+8.47%) Jun 7
At Loss
P/B:
1.31
Market Cap:
kr 44.92M ($ 4.24M)
Enterprise V:
kr 4.21M ($ 398.00K)
Volume:
636.06K
Avg Vol (2M):
197.54K
Also Trade In:
Volume:
636.06K
At Loss
Avg Vol (2M):
197.54K

Business Description

Description
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.76
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 89.15
9-Day RSI 79.58
14-Day RSI 69.51
6-1 Month Momentum % -80.76
12-1 Month Momentum % -70.61

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.23
Quick Ratio 4.23
Cash Ratio 4.16

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.2
Shareholder Yield % -60.35

Profitability Rank

Name Current Vs Industry Vs History
ROE % -80.65
ROA % -52.82
ROIC % -201.73
ROCE % -77.02

Financials (Next Earnings Date:2024-08-29)

OSTO:ELIC's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Elicera Therapeutics AB Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr)
EPS (TTM) (kr) -0.98
Beta 0
Volatility % 142.87
14-Day RSI 69.51
14-Day ATR (kr) 0.102117
20-Day SMA (kr) 0.9938
12-1 Month Momentum % -70.61
52-Week Range (kr) 0.852 - 7.24
Shares Outstanding (Mil) 35.09

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Elicera Therapeutics AB Filings

Filing Date Document Date Form
No Filing Data

Elicera Therapeutics AB Stock Events

Financials Calendars
Event Date Price(kr)
No Event Data

Elicera Therapeutics AB Frequently Asked Questions

What is Elicera Therapeutics AB(OSTO:ELIC)'s stock price today?
The current price of OSTO:ELIC is kr1.28. The 52 week high of OSTO:ELIC is kr7.24 and 52 week low is kr0.85.
When is next earnings date of Elicera Therapeutics AB(OSTO:ELIC)?
The next earnings date of Elicera Therapeutics AB(OSTO:ELIC) is 2024-08-29.
Does Elicera Therapeutics AB(OSTO:ELIC) pay dividends? If so, how much?
Elicera Therapeutics AB(OSTO:ELIC) does not pay dividend.

Press Release

Subject Date
No Press Release